Chimeric Therapeutics Limited (ASX:CHM)

Market Cap	9.76M
Revenue (ttm)	12.68M
Net Income (ttm)	-10.43M
Shares Out	3.25B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,493,404
Average Volume	9,731,007
Open	0.0030
Previous Close	0.0030
Day's Range	0.0030 - 0.0030
52-Week Range	0.0020 - 0.0140
Beta	1.55
RSI	48.14
Earnings Date	Aug 29, 2025

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

In 2025, Chimeric Therapeutics's revenue was 12.68 million, an increase of 70.09% compared to the previous year's 7.46 million. Losses were -10.43 million, -16.76% less than in 2024.